斑蝥胶囊对乳腺癌内分泌治疗患者生命质量影响的临床研究(4)
[11]Palmieri，C.，Patten，D.K.，Januszewski，A.，et al.Breast cancer：Current and future endocrine therapies[J].Molecular and Cellular Endocrinology，2014，382(1)：695-723.
[12]Hashimoto，K.，Shimizu，C.，Tsuda，H.，et al.Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome[J].Oncology：International Journal of Cancer Research and Treatment，2012，82(3)：168-174.
[13]Zhu，Y.，Li，Q.，Gao，J.，et al.Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy[J].The breast journal，2013，19(4)：382-387.
[14]Schiavon，G.，Smith，I.E..Endocrine therapy for advanced/metastatic breast cancer[J].Hematology/Oncology Clinics of North America，2013，27(4)：715-736.
[15]Delpech，Y.，Wu，Y.，Hess，K.R.，et al.Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer[J].Breast cancer research and treatment，2012，135(2)：619-627.
[16]Charehbili，A.，Fontein，D.B.Y.，Kroep，J.R.，et al.Neoadjuvant hormonal therapy for endocrine sensitive breast cancer：A systematic review[J].Cancer Treatment Reviews，2014，40(1)：86-92., 百拇医药(吴池华 李一 杨麟翰 贾新建)
[12]Hashimoto，K.，Shimizu，C.，Tsuda，H.，et al.Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome[J].Oncology：International Journal of Cancer Research and Treatment，2012，82(3)：168-174.
[13]Zhu，Y.，Li，Q.，Gao，J.，et al.Clinical features and treatment response of solid neuroendocrine breast carcinoma to adjuvant chemotherapy and endocrine therapy[J].The breast journal，2013，19(4)：382-387.
[14]Schiavon，G.，Smith，I.E..Endocrine therapy for advanced/metastatic breast cancer[J].Hematology/Oncology Clinics of North America，2013，27(4)：715-736.
[15]Delpech，Y.，Wu，Y.，Hess，K.R.，et al.Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer[J].Breast cancer research and treatment，2012，135(2)：619-627.
[16]Charehbili，A.，Fontein，D.B.Y.，Kroep，J.R.，et al.Neoadjuvant hormonal therapy for endocrine sensitive breast cancer：A systematic review[J].Cancer Treatment Reviews，2014，40(1)：86-92., 百拇医药(吴池华 李一 杨麟翰 贾新建)